Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Neuro-Oncology

• Publication date

  2017-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/neuonc/nox026PMID 28371827PMCID PMC5570198
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

  2016cited by this paper
• Inactivation of the ATMIN/ATM pathway protects against glioblastoma formation

  2016cited by this paper
• MiR-422a acts as a tumor suppressor in glioblastoma by targeting PIK3CA.

  2016cited by this paper
• The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy

  2016cited by this paper
• Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

  2016cited by this paper
• Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses.

  2016cited by this paper
• Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.

  2016cited by this paper
• Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.

  2016cited by this paper
• Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM).

  2016cited by this paper
• Admixture into and within sub-Saharan Africa

  2016cited by this paper
• Sequential immune checkpoint inhibition with concurrent bevacizumab for relapsed glioblastoma: A single centre experience.

  2016cited by this paper
• Safety and activity of nivolumab (nivo) monotherapy and nivo in combination with ipilimumab (ipi) in recurrent glioblastoma (GBM): Updated results from checkmate-143.

  2016cited by this paper
• Next‐generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma

  2016cited by this paper
• Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels.

  2016cited by this paper
• Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.

  2016cited by this paper
• Biomarkers in cancer immunotherapy.

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2015cited by this paper
• Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

  2015cited by this paper
• Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers

  2015cited by this paper
• Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

  2015cited by this paper
• Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis.

  2015cited by this paper
• PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients

  2015cited by this paper
• Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.

  2015cited by this paper
• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

  2015cited by this paper
• IMCT-03SAFETY AND ACTIVITY OF NIVOLUMAB MONOTHERAPY AND NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN RECURRENT GLIOBLASTOMA: UPDATED RESULTS FROM CHECKMATE-143.

  2015cited by this paper
• IMCT-18PD-1 INHIBITORS FOR RECURENT HIGH GRADE GLIOMA (HGG)

  2015cited by this paper
• PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

  2015cited by this paper
• Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.

  2015cited by this paper
• Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

  2015cited by this paper
• Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial.

  2014cited by this paper
• Exomics and immunogenics

  2014cited by this paper
• Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type

  2014cited by this paper
• Genetic basis for clinical response to CTLA-4 blockade in melanoma.

  2014cited by this paper
• Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology

  2014cited by this paper
• Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

  2013cited by this paper
• The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma

  2010cited by this paper
• Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

  2010cited by this paper
• MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance

  2009cited by this paper
• Comprehensive genomic characterization defines human glioblastoma genes and core pathways

  2008cited by this paper
• Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment

  2007cited by this paper
• Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.

  2007cited by this paper
• A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.

  2006cited by this paper
• High Frequency of Mutations of the PIK3CA Gene in Human Cancers

  2004cited by this paper
• Mutation of the PIK3CA Gene in Ovarian and Breast Cancer

  2004cited by this paper
• Categorical Data Analysis

  2003cited by this paper
• Controlling the false discovery rate: a practical and powerful approach to multiple testing

  1995cited by this paper

• Multi‐Omics Evidence Based on Spatial Transcriptomics Data Reveals the Therapeutic Value of Copper Death Genes in Glioblastoma

  2026cites this paper
• CAR-T cell therapies are coming after glioblastoma: An overview of early phase clinical trials and future perspectives

  2026cites this paper
• The immune awakening: Transformative strategies against brain tumors.

  2026cites this paper
• Recent advances in immunotherapy for gliomas: overcoming barriers and advancing precision strategies

  2026cites this paper
• Tumor immunotherapy: past, present, and future

  2025cites this paper
• The current status of immune checkpoint inhibitors in pediatric CNS tumors: a systematic review with a representative case of CMMRD-associated glioma

  2025cites this paper
• Why Do Glioblastoma Treatments Fail?

  2025cites this paper
• Dual aVß8 Integrin and PD-1 Blockade Overcomes TGFβ-Mediated B-Cell Suppression to Enhance Anti-Tumor Immunity

  2025cites this paper
• Within and beyond the tumor: Mechanisms of glioblastoma-induced immunosuppression

  2025cites this paper
• Germline pathogenic variation impacts somatic alterations and patient outcomes in pediatric CNS tumors

  2025cites this paper
• The glioma microenvironment and its impact on antitumor immunity

  2025cites this paper
• Machine learning-based integration develops a hypoxia-derived signature for improving outcomes in glioma

  2025cites this paper
• Comprehensive Characterization of the Immune Microenvironment Based on Nested Resampling Machine Learning Framework Identifies TRAF3 Interacting Protein 3 as a Promising Regulator to Improve the Resistance to Immunotherapy in Glioma

  2025cites this paper
• Biomarkers of immunotherapy response in neuro-oncology

  2025cites this paper
• Germline pathogenic variation impacts somatic alterations and patient outcomes in pediatric central nervous system tumors

  2025cites this paper
• KCTD9 expression predicts immunotherapy response and enhances anti-PD-1 efficacy in colon adenocarcinoma

  2025cites this paper
• [Development of Antibody-polymer Conjugates for the Treatment of Intractable Cancers].

  2025cites this paper
• Unveiling MMR deficiency in pediatric and AYA high-grade gliomas: insights from multiomic profiling

  2025cites this paper
• Immune checkpoint blockade in glioblastoma: overcoming barriers through mechanism-informed, biomarker-guided, and combinatorial immunotherapies targeting the tumor microenvironment and validated by clinical trials

  2025cites this paper
• Tertiary lymphoid structures achieve 'cold' to 'hot' transition by remodeling the cold tumor microenvironment.

  2025cites this paper
• Immune Cell Interplay in the Fight Against GBM

  2025cites this paper
• Peptide‑based therapeutic strategies for glioma: current state and prospects.

  2025cites this paper
• Increased immunogenicity of hypermutated SB28 syngeneic glioblastoma is partially mediated by alterations in tumor chemokine expression.

  2025cites this paper
• VALIDAÇÃO DE DADOS IN SILICO DE BIOMARCADORES IMUNOLÓGICOS E ALVOS DE IMUNOTERAPIA NO GLIOBLASTOMA IDH- WILDTYPE PELA IMUNO-HISTOQUÍMICA

  2025cites this paper
• Immune Resistance in Glioblastoma: Understanding the Barriers to ICI and CAR-T Cell Therapy

  2025influential citation
• Prognostic significance of PD-L1 and CD45RO+ cells in glioblastoma: The modulating role of MMR status.

  2025cites this paper
• Targeting TGFβ docking receptor Glycoprotein A Repetitions Predominant (GARP) via novel chimeric antigen receptor (CAR)-T cell platform to treat glioblastoma.

  2025cites this paper
• Immune Scenario Identification Combining Multiplexed, Quantitative, and Advanced Imaging Analysis Could Be Relevant in Immunotherapy against Glioblastoma and Grade 4 Astrocytoma

  2025cites this paper
• Identification of lung adenocarcinoma subtypes and a prognostic signature based on activity changes of the hallmark and immunologic gene sets

  2024cites this paper
• Immunotherapeutic Strategies for the Treatment of Glioblastoma: Current Challenges and Future Perspectives

  2024cites this paper
• mRNA-based precision targeting of neoantigens and tumor-associated antigens in malignant brain tumors

  2024cites this paper
• Novel Clinical Trials and Approaches in the Management of Glioblastoma

  2024cites this paper
• Emerging trends and thematic evolution of immunotherapy for glioma based on the top 100 cited articles

  2024cites this paper
• Decoding the DNA methylome of central nervous system tumors: An emerging modality for integrated diagnosis

  2024cites this paper
• The role of radiotherapy in immunotherapy strategies in the central nervous system.

  2024cites this paper
• Impact of tissue-agnostic approvals on management of primary brain tumors.

  2024cites this paper
• Case report: Temozolomide induced hypermutation indicates an unfavorable response to immunotherapy in patient with gliomas.

  2024cites this paper
• Lynch Syndrome-Associated Glioblastoma Treated With Concomitant Chemoradiotherapy and Immune Checkpoint Inhibitors: Case Report and Review of Literature

  2024cites this paper
• Genetic and epigenetic instability as an underlying driver of progression and aggressive behavior in IDH-mutant astrocytoma

  2024cites this paper
• Pediatric glioma immune profiling identifies TIM3 as a therapeutic target in BRAF fusion pilocytic astrocytoma

  2024cites this paper
• An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas

  2024cites this paper
• Immune Checkpoint Inhibitors in Glioblastoma IDHwt Treatment: A Systematic Review

  2024cites this paper
• Pathological diagnosis of central nervous system tumours in adults: what's new?

  2024cites this paper
• Suppressive immune microenvironment and CART therapy for glioblastoma: future prospects and challenges.

  2024cites this paper
• The Role of Mesenchymal Reprogramming in Malignant Clonal Evolution and Intra-Tumoral Heterogeneity in Glioblastoma

  2024cites this paper
• Immunomodulatory signalling networks in glioblastoma multiforme: a comprehensive review of therapeutic approaches

  2024cites this paper
• Genomic Profiling in Glioma Patients to Explore Clinically Relevant Markers

  2024cites this paper
• Multidimensional analysis of matched primary and recurrent glioblastoma identifies contributors to tumor recurrence influencing time to relapse

  2024cites this paper
• Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy?

  2024cites this paper
• Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape

  2024cites this paper
• Research hotspots and trend of glioblastoma immunotherapy: a bibliometric and visual analysis

  2024cites this paper
• Glioblastoma and Immune Checkpoint Inhibitors: A Glance at Available Treatment Options and Future Directions

  2024cites this paper
• Current status of precision oncology in adult glioblastoma

  2024cites this paper
• Targeting Pediatric Solid Tumors in the New Era of RNA Therapeutics.

  2024cites this paper
• Necroptosis-based glioblastoma prognostic subtypes: implications for TME remodeling and therapy response

  2024cites this paper
• The challenges and clinical landscape of glioblastoma immunotherapy

  2024influential citation
• Diagnostic Accuracy of Ambient Mass Spectrometry with Blood Plasma in a Murine Glioma Model Using Machine Learning.

  2024cites this paper
• A Synopsis of Biomarkers in Glioblastoma: Past and Present

  2024cites this paper
• Assessment of the clinical effectiveness and safety of immune checkpoint inhibitors for glioblastoma: A systematic review

  2023cites this paper
• Novel Therapies in Glioblastoma Treatment: Review of Glioblastoma; Current Treatment Options; and Novel Oncolytic Viral Therapies

  2023cites this paper
• Analysis of Histomorphologic/Molecular Association and Immune Checkpoint Regulators in Epithelioid Glioblastoma and Pleomorphic Xanthoastrocytoma: Are These Tumors Potential Candidates for Immune Checkpoint Blockade?

  2023influential citation
• Immune Checkpoint Inhibitors and Glioblastoma: A Review on Current State and Future Directions

  2023cites this paper
• A TGF‐β signaling‐related lncRNA signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response

  2023cites this paper
• The Use of Targeted Cytokines as Cancer Therapeutics in Glioblastoma

  2023cites this paper
• Knowledge structure and hotspots research of glioma immunotherapy: a bibliometric analysis

  2023cites this paper
• P53-negative status and gross total resection as predictive factors for autologous tumor vaccine treatment in newly diagnosed glioblastoma patients

  2023cites this paper
• Characteristics of glioblastomas and immune microenvironment in a Chinese family with Lynch syndrome and concurrent porokeratosis

  2023cites this paper
• Immunotherapeutic Approaches for the Treatment of Glioblastoma Multiforme: Mechanism and Clinical Applications

  2023cites this paper
• The Development of Immunotherapy for the Treatment of Recurrent Glioblastoma

  2023influential citation
• Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators

  2023cites this paper
• Genome-wide profiling of patient-derived glioblastoma stem-like cells reveals recurrent genetic and transcriptomic signatures associated with brain tumors

  2023cites this paper
• Multiple therapeutic approaches of glioblastoma multiforme: From terminal to therapy.

  2023cites this paper
• Mismatch repair–deficient glioma with spatially distinct IDH-mutant and IDH-wild type components arising in the setting of Lynch syndrome

  2023cites this paper
• CD103+ regulatory T cells underlie resistance to radio-immunotherapy and impair CD8+ T cell activation in glioblastoma

  2023cites this paper
• Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade

  2023cites this paper
• Novel Immunotherapeutic Approaches for the Treatment of Glioblastoma

  2023cites this paper
• Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models

  2023cites this paper
• B-cells Drive Response to PD-1 Blockade in Glioblastoma Upon Neutralization of TGFβ-mediated Immunosuppression

  2023cites this paper
• Recent Developments in Glioblastoma Therapy: Oncolytic Viruses and Emerging Future Strategies

  2023cites this paper
• Cilia at the Crossroads of Tumor Treating Fields and Chemotherapy

  2023cites this paper
• Targeting Microglial Metabolic Rewiring Synergizes with Immune Checkpoint Blockade Therapy for Glioblastoma.

  2023cites this paper
• Immunotherapy-Related Biomarkers: Confirmations and Uncertainties.

  2023cites this paper
• Novel Murine Glioblastoma Models That Reflect the Immunotherapy Resistance Profile of Human Disease.

  2023cites this paper
• Multidimensional analysis of matched primary and recurrent glioblastoma identifies Fcγ receptors upregulation on microglia as a contributor of tumor recurrence

  2023cites this paper
• Identification and validation of a PD-L1-related signature from mass spectrometry in gastric cancer

  2023cites this paper
• TSPO acts as an immune resistance gene involved in the T cell mediated immune control of glioblastoma

  2023cites this paper
• Signaling pathways in brain tumors and therapeutic interventions

  2023cites this paper
• Events in CNS Tumor Pathology Post-2016 WHO CNS: cIMPACT-NOW Updates and Other Advancements: A Comprehensive Review Plus a Summary of the Salient Features of 2021 WHO CNS 5

  2023cites this paper
• Construction of an original anoikis-related prognostic model closely related to immune infiltration in gastric cancer

  2023cites this paper
• Machine learning to improve interpretability of clinical, radiological and panel-based genomic data of glioma grade 4 patients undergoing surgical resection

  2023cites this paper
• Pan-cancer analyses reveal IGSF10 as an immunological and prognostic biomarker

  2023cites this paper
• Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment

  2023cites this paper
• Progress in phase III clinical trials of molecular targeted therapy and immunotherapy for glioblastoma

  2023cites this paper
• CYP19A1 promotes gastric cancer as part of a lipid metabolism-related gene signature related to the response of immunotherapy and prognosis

  2023cites this paper
• Integrative analysis to screen novel pyroptosis-related LncRNAs for predicting clinical outcome of glioma and validation in tumor tissue

  2023cites this paper
• Next Steps for Immunotherapy in Glioblastoma

  2022cites this paper
• Emerging role of ferroptosis in glioblastoma: Therapeutic opportunities and challenges

  2022cites this paper
• Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy.

  2022cites this paper
• Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds

  2022cites this paper
• Recurrent Glioblastoma Treatment: State of the Art and Future Perspectives in the Precision Medicine Era

  2022cites this paper